ATN-161

• Description:

  ATN-161 is a novel integrin α5β1 antagonist, which inhibits angiogenesis and growth of liver metastases in a murine model.

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  Integrin

• Type:

  Reference compound

• Related Pathways:

  Cytoskeleton

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/atn-161.html

• Purity:

  99.36

• Solubility:

  DMSO : 25 mg/mL (ultrasonic) |H2O : 10 mg/mL

• Smiles:

  O=C(N)C[C@@H](C(N)=O)NC([C@H](CS)NC([C@H](CO)NC([C@H](CC1=CNC=N1)NC([C@H]2N(C(C)=O)CCC2)=O)=O)=O)=O

• Molecular Formula:

  C23H35N9O8S

• Molecular Weight:

  597.64

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Stoeltzing O, et al. Inhibition of integrin alpha5beta1 function with a small peptide (ATN-161) plus continuous 5-FU infusion reduces colorectal liver metastases and improves survival in mice. Int J Cancer. 2003 Apr 20;104 (4) :496-503.|[2]Wang W, et al. The antiangiogenic effects of integrin alpha5beta1 inhibitor (ATN-161) in vitro and in vivo. Invest Ophthalmol Vis Sci. 2011 Sep 14;52 (10) :7213-20.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 2

• Citation 01:

  ACS Nano. 2025 Jun 10;19 (22) :20564-20577.|Cancer Cell. 2019 Jan 14;35 (1) :64-80.e7. |J Adv Res. 2025 May 25:S2090-1232 (25) 00370-4.|Sci Signal. 2022 Dec 6;15 (763) :eabn2743.|ACS Biomater Sci Eng. 2023 May 8;9 (5) :2524-2533.|Cell Prolif. 2021 Apr;54 (4) :e13012.|Colloids Surf B Biointerfaces. 2022 Feb:210:112227.|Stem Cell Res Ther. 2022 Jul 18;13 (1) :327.

• CAS Number:

  [262438-43-7]